Lipase News and Research

RSS

Leading journal publishes article about ciliate lipases as therapeutic candidates for oral treatment of EPI

Cilian AG, a biopharmaceutical company focused on the development of subunit vaccines, enzymes and monoclonal antibodies, announces that the European Journal of Gastroenterology & Hepatology, the international, peer-reviewed, online publication journal, has published an article entitled: Novel ciliate lipases for enzyme replacement during exocrine pancreatic insufficiency.

20 Dec 2016

Single gene therapy for lipoprotein lipase deficiency reduces severity and frequency of pancreatitis

Over a 6-year period, patients with the genetic disease lipoprotein lipase deficiency (LPLD) who received a single gene therapy treatment of alipogene tiparvovec had a marked reduction in the severity and frequency of pancreatitis.

8 Nov 2016

Gene therapy for LPLD patients linked to lower frequency and severity of pancreatitis

Up to 6 years after receiving a single treatment with the gene therapy product lipoprotein lipase (LPL), patients with the debilitating genetic disease LPL deficiency (LPLD) had about 50% fewer episodes of pancreatitis than before receiving the treatment.

28 Sep 2016

Alexion initiates new global Uncommon Strength campaign to raise awareness of rare diseases

Alexion Pharmaceuticals, Inc. today announced the launch of Uncommon Strength, a global campaign to raise awareness of rare diseases through the celebration of the extraordinary resilience and inner strength of those impacted by these diseases.

15 Sep 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.

18 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Specific gene mutation may significantly reduce risk of heart attack

People with a specific gene mutation have a 50 percent lower risk of suffering a heart attack. This is what an international team of researchers headed by the cardiologist Prof. Heribert Schunkert, Medical Director of the German Heart Center at the Technical University of Munich (TUM), discovered in a broad comparative study. If this gene were switched off with medications it could reduce the risk of coronary disease significantly.

10 Mar 2016

Genetic errors may reduce heart attack risk, study finds

To reduce risk of heart attack, the benefits of a healthy lifestyle are clear. But genetics can still stack the deck. Some people's genes bestow a natural advantage — or disadvantage — in protecting against heart disease, the leading cause of death worldwide.

3 Mar 2016

Cells with higher fat content live longer than lean cells

Cells with higher fat content outlive lean cells, says a new study from Michigan State University.

24 Feb 2016

Enzyme screening kits and samples global distribution agreement signed between Strem and Novozymes

Strem Chemicals, Inc., a manufacturer of specialty chemicals for research and development, and Novozymes, the world’s largest producer of industrial enzymes, today announced the signing of a distribution agreement.

17 Feb 2016

Confirming nasogastric tube placement through an assay? An interview with Ian Fotheringham

Nasogastric tubes are placed directly into the stomach in order to feed or medicate patients. If an NG tube accidentally goes into the lung instead, which can happen, it can cause serious harm to the patient, with food, liquid or medication potentially entering the lung.

15 Feb 2016

Study identifies FGF21 protein as potential therapeutic agent for cardiovascular diseases, type 2 diabetes

New research on the blood lipid-lowering protein FGF21 shows how it redistributes fatty acids by two distinct mechanisms. The discovery could lead to improved pharmaceutical treatment for type 2 diabetes and other obesity-related diseases.

11 Feb 2016

Vanderbilt study offers a glimmer of hope to alcoholics suffering from depression

A study by researchers at Vanderbilt University Medical Center is offering a glimmer of hope to alcoholics who find it hard to remain sober because their abstinence is hounded by stubborn, difficult-to-treat depression.

1 Feb 2016

TSRI scientists discover molecular ‘switch’ that could reduce nicotine addiction

Scientists at The Scripps Research Institute have discovered that a lipid in brain cells may act as a “switch” to increase or decrease the motivation to consume nicotine.

19 Jan 2016

UF researchers reveal link between chronic stress and fat metabolism

In cell and mouse model experiments, University of Florida Health researchers have discovered that chronic stress stimulates production of betatrophin, a protein that then goes on to inhibit an enzyme involved in fat metabolism.

7 Jan 2016

Cholesterol essential for health, but also plays key role in longevity

Animals from tiny worms to human beings have a love-hate relationship with fats and lipids. Cholesterol is a famous example of how they are both essential for health and often have a role in death.

23 Dec 2015

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

8 Dec 2015

Ingenza and Imperial researchers work together to improve nasogastric feeding tube placement

Ingenza has teamed up with clinical scientists at Imperial College London to trial an improved diagnostic assay for confirming nasogastric (NG) tube placement. Professor George Hanna, Director of the National Institute for Health Research Diagnostic Evidence Co-operative London at Imperial College Healthcare NHS Trust, which specialises in In Vitro Diagnostics, explained: “Correct placement of NG tubes is vital, as accidental insertion of the tube into the lung instead of the gut can have serious consequences.

3 Nov 2015

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies.

10 Sep 2015